About Cumberland Pharmaceuticals, Inc. 
Cumberland Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).
Company Coordinates 
Company Details
2525 W End Ave Ste 950 , NASHVILLE TN : 37203-1608
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 7 Schemes (7.66%)
Foreign Institutions
Held by 4 Foreign Institutions (0.2%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. A. Kazimi
Chairman of the Board, Chief Executive Officer
Mr. Martin Cearnal
Executive Vice President, Chief Commercial Officer, Director
Dr. Gordon Bernard
Independent Director
Mr. Joseph Galante
Independent Director
Mr. Jonathan Griggs
Independent Director
Mr. Joey Jacobs
Independent Director
Mr. James Jones
Independent Director
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
Pharmaceuticals & Biotechnology
USD 50 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.37
-10.96%
1.77






